SRR975560
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- MYOGENESIS+0.280
- KRAS_SIGNALING_DN+0.260
- COAGULATION+0.220
- ESTROGEN_RESPONSE_LATE+0.210
- P53_PATHWAY+0.200
- TGF_BETA_SIGNALING+0.170
- APICAL_JUNCTION+0.160
- OXIDATIVE_PHOSPHORYLATION+0.160
Top 10 suppressed
- G2M_CHECKPOINT-0.570
- E2F_TARGETS-0.550
- MYC_TARGETS_V2-0.540
- MYC_TARGETS_V1-0.520
- UNFOLDED_PROTEIN_RESPONSE-0.440
- MTORC1_SIGNALING-0.410
- PROTEIN_SECRETION-0.350
- ALLOGRAFT_REJECTION-0.300
- MITOTIC_SPINDLE-0.280
- IL6_JAK_STAT3_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1403222 | GTEX | — | 0.827 |
| 2 | 60c210ff-d245-40d2-9de9-7b799cc3ffc9 | — | — | 0.805 |
| 3 | SRR1324043 | GTEX | — | 0.804 |
| 4 | SRR25617932 | — | A | 0.790 |
| 5 | SRR1315761 | GTEX | — | 0.786 |
| 6 | TCGA-GM-A2D9-01A-11R-A18M-07 | — | B | 0.785 |
| 7 | MNG1114 | — | — | 0.783 |
| 8 | TCGA-AC-A3W7-01A-11R-A22K-07 | — | A | 0.774 |
| 9 | SRR1382570 | GTEX | — | 0.770 |
| 10 | MNG25 | — | — | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| APOPTOSIS | 0.030 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |